Waleed H. Hassanein

President, CEO, and Director at TransMedics Group

Board

Since August 1998

Age

55 years

Education

Earned his M.D. degree from Georgetown University in 1993 after attending Cairo University School of Medicine from 1985 to 1989 and holds a General Certificate of Education from the University of London.

Tenure

Has served as founder, President, CEO, and Director at TMDX since August 1998.

Also at TransMedics Group

Anil Ranganath

SVP, General Counsel, Secretary

Gerardo Hernandez

Chief Financial Officer (CFO)

Nick Corcoran

SVP, Supply Chain and Operations

About

Waleed H. Hassanein, M.D. is a seasoned leader in the medical field and the founding executive at TMDX. Born in 1969, his clinical and surgical background has been pivotal in shaping his strategic vision and operational approach.

He initiated his academic journey at Cairo University School of Medicine before transferring to Georgetown University, where he earned his M.D. degree in 1993. In addition, he holds a General Certificate of Education from the University of London, which further underscores his diverse educational background in medicine.

Since August 1998, he has been at the helm of TMDX, serving as its founding President, CEO, and Director. His extensive experience, including a three-year cardiac surgery research fellowship and two years of general surgery residency, has been integral to the growth and success of the company.

$TMDX Performance Under Waleed H. Hassanein

Past Roles

Organization	Role	Date Range	Details
West Roxbury VA Medical Center / Brigham and Women’s Hospital	Cardiac Surgery Research Fellowship	N/A	Three-year fellowship; affiliated with Harvard Medical School
Georgetown University Medical Center	General Surgery Residency	N/A	Two-year residency conducted prior to fellowship

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$650,000	Annual	Increased from $590,000 in 2022; 10.2% increase
Company 401(k) Matching Contributions	$13,200	Annual	Standard company contribution as per plan
Group Term Life Insurance Premium	$450	Annual	Premium paid by the company for group term life insurance

Performance Compensation

Data from FY 2023

Cash Bonus Compensation

Metric	Threshold	Target	Maximum	Actual Achievement
Revenue	80% of $144M = $115.2M	$144M	$187M or more	$241.6M
Strategic Goals	3 out of 5	N/A	N/A	5 out of 5
Bonus Payout	N/A	$585,000	200% of target; $1,170,000	$1,170,000
Evaluation Period	N/A	N/A	N/A	2023

Equity Awards Compensation

Component	Grant Date	Grant Date Fair Value	Grant Date Stock Price	Vesting Schedule
RSUs	Feb 20, 2023	$2,467,645	$66.10	Vest annually over 3 years
Stock Options	Feb 20, 2023	$2,472,929	$66.10	Vest monthly over 4 years